Renalytix AI
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a… Read more
Renalytix AI (RNLX) - Net Assets
Latest net assets as of June 2024: $-7.85 Million USD
Based on the latest financial reports, Renalytix AI (RNLX) has net assets worth $-7.85 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.97 Million) and total liabilities ($15.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-7.85 Million |
| % of Total Assets | -98.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | -121.84% |
| 10-Year Change | N/A |
| Growth Volatility | 103.55 |
Renalytix AI - Net Assets Trend (2018–2024)
This chart illustrates how Renalytix AI's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Renalytix AI (2018–2024)
The table below shows the annual net assets of Renalytix AI from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-06-30 | $-7.85 Million | -142.56% |
| 2023-06-30 | $18.45 Million | -57.25% |
| 2022-06-30 | $43.17 Million | -54.61% |
| 2021-06-30 | $95.10 Million | +164.45% |
| 2020-06-30 | $35.96 Million | +27.67% |
| 2019-06-30 | $28.17 Million | +300100.00% |
| 2018-06-30 | $-9.39K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Renalytix AI's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21170282700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $478.00K | % |
| Other Comprehensive Income | $-1.44 Million | % |
| Other Components | $204.89 Million | % |
| Total Equity | $-7.85 Million | 100.00% |
Renalytix AI Competitors by Market Cap
The table below lists competitors of Renalytix AI ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Scienture Holdings, Inc.
NASDAQ:SCNX
|
$16.12 Million |
|
Australian Vintage Ltd
PINK:AUVGF
|
$16.12 Million |
|
Yuan Jen Enterprises Co Ltd
TW:1725
|
$16.12 Million |
|
NSE S.A. EO 155
F:7YM
|
$16.12 Million |
|
Archer Entertainment Media Communications Inc.
PINK:CBLO
|
$16.10 Million |
|
Central Motek Co Ltd
KO:308170
|
$16.10 Million |
|
MARKEL CORP (MKV.SG)
STU:MKV
|
$16.09 Million |
|
Gamehaus Holdings Inc. Class A Ordinary Shares
NASDAQ:GMHS
|
$16.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Renalytix AI's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 18,454,000 to -7,854,000, a change of -26,308,000 (-142.6%).
- Net loss of 33,456,000 reduced equity.
- New share issuances of 13,626,000 increased equity.
- Other comprehensive income increased equity by 7,000.
- Other factors decreased equity by 6,485,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.46 Million | -425.97% |
| Share Issuances | $13.63 Million | +173.49% |
| Other Comprehensive Income | $7.00K | +0.09% |
| Other Changes | $-6.49 Million | -82.57% |
| Total Change | $- | -142.56% |
Book Value vs Market Value Analysis
This analysis compares Renalytix AI's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-06-30 | $0.00 | $0.14 | x |
| 2019-06-30 | $1.32 | $0.14 | x |
| 2020-06-30 | $1.22 | $0.14 | x |
| 2021-06-30 | $1.33 | $0.14 | x |
| 2022-06-30 | $0.58 | $0.14 | x |
| 2023-06-30 | $0.22 | $0.14 | x |
| 2024-06-30 | $-0.07 | $0.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Renalytix AI utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1461.60%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-72.33%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -19.74% | 0.00% | 0.00x | 1.03x | $-8.38 Million |
| 2020 | -25.72% | 0.00% | 0.00x | 1.15x | $-12.85 Million |
| 2021 | -36.51% | -2328.97% | 0.01x | 1.08x | $-44.24 Million |
| 2022 | -104.88% | -1524.44% | 0.05x | 1.47x | $-49.59 Million |
| 2023 | -247.14% | -1340.20% | 0.08x | 2.28x | $-47.45 Million |
| 2024 | 0.00% | -1461.60% | 0.29x | 0.00x | $-32.67 Million |
Industry Comparison
This section compares Renalytix AI's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $79,108,599
- Average return on equity (ROE) among peers: -247.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Renalytix AI (RNLX) | $-7.85 Million | -19.74% | N/A | $16.11 Million |
| Accolade, Inc. (ACCD) | $473.79 Million | -97.02% | 0.91x | $448.32 Million |
| Achiko AG (ACHKF) | $-4.58 Million | 0.00% | 0.00x | $314.42K |
| Ascom Holding AG (ACMLF) | $78.70 Million | 22.11% | 1.51x | $152.13 Million |
| Accelera Innovations Inc (ACNV) | $-462.52K | 0.00% | 0.00x | $5.72K |
| Aclarion Inc (ACON) | $-7.08 Million | 0.00% | 0.00x | $1.89 Million |
| Alternate Health Corp (AHGIF) | $1.07 Million | -2231.82% | 7.94x | $6.50K |
| AI/ML Innovations Inc (AIMLF) | $2.09 Million | -130.52% | 0.72x | $6.84 Million |
| NetraMark Holdings Inc. (AINMF) | $-198.56K | 0.00% | 0.00x | $70.13 Million |
| AMJ Global Technology (AMJT) | $-21.78K | 0.00% | 0.00x | $10.99 Million |
| American Well Corp (AMWL) | $247.79 Million | -38.62% | 0.31x | $78.62 Million |